Clinical trial
Endocrine Therapy With or Without Anti-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865) for Women With Hormone Receptor-Positive Advanced Breast Cancer
NCT00601900 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Endocrine Therapy With or Without Anti-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865) for Women With Hormone Receptor-Positive Advanced Breast Cancer
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 24, 2008
- Completion date
- January 29, 2024
- Enrollment
- 394 (actual)
- Sites
- 522
Conditions
As the registry lists them; a condition with its own page is linked.
invasive breast carcinoma, recurrent breast carcinoma, stage iii breast cancer ajcc v6, stage iv breast cancer ajcc v6 and v7